New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
18:55 EDTAMGN, NDLS, AZPN, CSCO, CNAT, KNDOn The Fly: After Hours Movers
UP AFTER EARNINGS: Aspen Technology (AZPN), up almost 3% after reporting better than expected Q4 results and giving Q1 and FY15 guidance on its earnings conference call. ALSO HIGHER: Kindred Healthcare (KND), up more than 1% after Point72 reported a 5.1% passive stake in the company. DOWN AFTER EARNINGS: Cisco Systems (CSCO), down 1.2% after reporting Q4 results, giving Q1 guidance, and announcing that it is cutting 8% of its workforce... Noodles & Company (NDLS), down 21.2% after reporting Q2 results and "tempering" its FY14 outlook... Conatus Pharmaceuticals (CNAT), down 13.6% after reporting Q2 results and announcing it is deferring the results of its NAFLD/NASH clinical trial to 1Q15. ALSO LOWER: Amgen (AMGN), down 2.15% after announcing the Phase 3 Kyprolis FOCUS clinical trial did not meet its primary endpoint.
News For AZPN;KND;CSCO;NDLS;CNAT;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
February 5, 2016
06:03 EDTAMGNAmgen resumed with a Market Perform at Leerink
Leerink analyst Geoffrey Porges resumed coverage of Amgen with a Market Perform rating and $179 price target.
February 4, 2016
19:15 EDTAMGNAmgen reinitiated with a Market Perform at Leerink
Target $179.
16:28 EDTAMGNAmgen reports BLINCYTO study met primary endpoint, stopped early for efficacy
Amgen announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus standard of care in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The independent data monitoring committee recommended, and Amgen has accepted, that the study end early for efficacy. The BLINCYTO adverse events observed in the TOWER study were consistent with the known safety profile of BLINCYTO. Secondary endpoints are currently being evaluated.
16:02 EDTAMGNAmgen says trial of Repatha meets co-primary endpoints
Subscribe for More Information
February 3, 2016
16:40 EDTCSCOCisco and Jasper Technologies hold a joint conference call
Cisco Vice President Salvagno and Jasper Technologies CEO Mohammed discuss Cisco's intent to acquire Jasper Technologies on a joint conference call to be held on February 3 at 5 pm. Webcast Link
16:19 EDTCSCOCisco to acquire Jasper Technologies for $1.4B
Subscribe for More Information
14:36 EDTCSCOArista shares jump as analysts encouraged patent issues can be overcome
Shares of Arista Networks (ANET) jumped Wednesday after the U.S. International Trade Commission reached an initial determination in the first of the company's ongoing patent disputes with Cisco (CSCO). The findings, though not entirely in Arista's favor, were cheered by several Wall Street analysts, who foresee little to no impact on Arista's business from the patent fight. NO BUSINESS IMPACT: Oppenheimer analyst Ittai Kidron argued today that, while the ITC's early ruling found Arista in violation of three of the five Cisco patents in question, the company already has workarounds for two of the disputed patents and is working on a third. That last workaround is scheduled for a second quarter rollout and could potentially miss the final determination deadline, but Kidron explained that Arista would simply work with U.S. Customs on the matter at that point. The analyst expects Arista to take the necessary steps to preempt any disruption and foresees zero impact to its business, leading him to keep an Outperform rating on the shares and recommends buying them on any weakness. Kidron noted, however, that the stock could be volatile surrounding the final determination in early June and the rulings for the second ITC investigation, due late April and August. ARISTA ATTRACTIVE: Wells Fargo analyst Jess Lubert echoed Kidron's bullish outlook, saying the ITC findings were largely as expected and "more than priced into" the shares. Arista's story remains attractive, customer sentiment is unlikely to be affected, and securing approval for the Q2 software workaround is "unlikely to be a problem," said the analyst, adding that the additional engineering costs associated with the fix appear already embedded in Arista's financial model. Lubert kept an Outperform rating on the shares, though he too noted potential volatility surrounding future legal findings. PRICE ACTION: Shares of Arista Networks have jumped 5.4% to $60.83, while Cisco has edged up nearly 1%.
09:19 EDTCNATOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
08:57 EDTAMGNPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
08:48 EDTAMGNWorkday appoints Diana McKenzie as Chief Information Officer
Subscribe for More Information
07:37 EDTCSCOArista Networks infringement 'largely priced into shares,' says Wells Fargo
Subscribe for More Information
07:32 EDTCNATConatus wins FDA fast track designation for Emricasan development
Subscribe for More Information
07:17 EDTCSCOArista Networks should be bought o nany weakness, says Oppenheimer
Subscribe for More Information
06:04 EDTCSCOCisco says ITC ruling 'beginning of the end' for Arista's copying
Cisco's (CSCO) Mark Chandler in a blog post last night commented on the International Trade Commission's ruling in the first of their investigations into Arista Networks (ANET). The judge found violations of three Cisco patents, foreshadowed an exclusion order banning imports of all Arista switches and installed a challenging ITC review process for any new designs, Chandler wrote. "The details of the Judge's determination will be published within 30 days, but this notice marks the beginning of the end for Arista's systemic copying of our intellectual property," he added. He listed four options for Arista: Withdraw the products, modify the products so that they no longer infringe, face an exclusion order or evade the ITC exclusion order. Chandler continued, "And this is just the beginning. In April we will see a ruling in the second ITC investigation, which may confirm more violations and import bans. Arista will also face two District Court juries with these rulings on their record. The judges and juries in those trials will note this day as the day that Arista no longer can pretend that its products aren't tainted by misconduct. This will be important as they consider injunctions to remove infringing Arista product from the market." Shares of Arista closed yesterday down $1.56 to $57.70. Cisco closed down 65c to $22.83. Reference Link
February 2, 2016
16:25 EDTCSCOArista responds to initial ruling in Cisco dispute, plans new software in Q2
Subscribe for More Information
15:50 EDTCSCOCisco looks to stop imports of Arista Networks routers, Bloomberg says
Arista (ANET), according to a U.S. trade judge, violates three Cisco (CSCO) patents, adds Bloomberg.
10:26 EDTCSCOFireEye calls active
Subscribe for More Information
10:18 EDTCSCOCisco could be interested in FireEye, dealReporter says citing sources
Subscribe for More Information
08:53 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:25 EDTAMGNAlder pullback Friday a buying opportunity, says Leerink
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use